It may not be a big pharma conspiracy but they sure as hell know how to wriggle through an approvals process.
ado were green on the approvals front to say the least and this was compounded by having a product which was just plain different
ado had the goods but missed the mark on jumping through the hoops.
if big pharma had seen value in reader options then the last twelve months would have been very very different for ado.
not saying the reader is not worth it. But its widespread use required a health provision paradigm shift which hasn't happened yet but imo will still occur.
Any positives?, page-317
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $55.39M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.3¢ | 2.2¢ | $119.3K | 5.253M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 861621 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 307735 | 3 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.2¢ |
Change
0.000 ( 4.35 %) |
||||
| Open | High | Low | Volume | ||
| 2.3¢ | 2.3¢ | 2.2¢ | 1089298 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| ADO (ASX) Chart |